Evidence map›Paper›PMID 35664993›Full record

ArticlebioRxiv : the preprint server for biology2022

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course.

Jonathan Muri, Valentina Cecchinato, Andrea Cavalli, Akanksha A Shanbhag, Milos Matkovic, Maira Biggiogero, Pier Andrea Maida, Jacques Moritz, Chiara Toscano, Elaheh Ghovehoud and 36 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors at 13 institutions in 7 countries.

Jonathan MuriInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Valentina CecchinatoInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Andrea CavalliInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Akanksha A ShanbhagInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Milos MatkovicInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Maira BiggiogeroClinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.
Pier Andrea MaidaClinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.
Jacques MoritzInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Chiara ToscanoInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Elaheh GhovehoudInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Raffaello FurlanDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
Franca BarbicDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
Antonio VozaDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
Guendalina De NadaiEmergency Medicine Residency School, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 - 20090 Pieve Emanuele, Milan, Italy.
Carlo CerviaDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Yves ZurbuchenDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Patrick TaeschlerDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Lilly A MurrayLyme & Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.
Gabriela Danelon-SargentiInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Simone MoroInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Tao GongInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Pietro PiffarettiInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Filippo BianchiniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Virginia CrivelliInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Lucie PodešvováInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Mattia PedottiInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
David JarrossayInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Jacopo SgrignaniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Sylvia ThelenInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Mario UhrSynlab Suisse; Bioggio, Switzerland.
Enos BernasconiRegional Hospital Lugano, Ente Ospedaliero Cantonale; Lugano, Switzerland.
Andri RauchDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern; Bern, Switzerland.
Antonio ManzoRheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia; Pavia, Italy.
Adrian CiureaDepartment of Rheumatology, Zurich University Hospital, University of Zurich; Zurich, Switzerland.
Marco B L RocchiDepartment of Biomolecular Sciences, Biostatistics Unit, University of Urbino; Urbino, Italy.
Luca VaraniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Bernhard MoserDivision of Infection & Immunity, Henry Wellcome Building, Cardiff University School of Medicine; Cardiff, United Kingdom.
Barbara BottazziIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
Marcus ThelenInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Brian A FallonLyme & Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.
Onur BoymanDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Alberto MantovaniDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
Christian GarzoniInternal Medicine and Infectious Diseases, Clinica Luganese Moncucco; Lugano, Switzerland.
Alessandra Franzetti-PellandaClinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.
Mariagrazia UguccioniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Università della Svizzera italiana · CHHumanitas University · ITUniversity of Zurich · CHClinica Luganese Moncucco · CHColumbia University Irving Medical Center · USInstitute of Infection and Immunity · CAIRCCS Humanitas Research Hospital · ITOspedale regionale di Lugano · CHSIB Swiss Institute of Bioinformatics · CHSynlab Czech (Czechia) · CZUniversity of Bern · CHUniversity of Pavia · ITUniversity of Urbino · IT

Funding

Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
Virology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2018 to 2022
$8.4M
NIAID NIH HHS P01 AI138938NIAID NIH HHS U01 AI151698NIAID NIH HHS U19 AI111825
6 · The paper itself

Abstract

Infection by SARS-CoV-2 leads to diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse COVID-19 outcomes. Instead, we discovered that antibodies against specific chemokines are omnipresent after COVID-19, associated with favorable disease, and predictive of lack of long COVID symptoms at one year post infection. Anti-chemokine antibodies are present also in HIV-1 infection and autoimmune disorders, but they target different chemokines than those in COVID-19. Monoclonal antibodies derived from COVID- 19 convalescents that bind to the chemokine N-loop impair cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising anti-chemokine antibodies associated with favorable COVID-19 may be beneficial by modulating the inflammatory response and thus bear therapeutic potential. One-Sentence Summary: Naturally arising anti-chemokine antibodies associate with favorable COVID-19 and predict lack of long COVID.

Identifiers

PMID35664993
PMCPMC9164443
OpenAlexW4281399690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.